Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double‐blind cross‐over study versus salbutamol

Publisher Website
Google Scholar
Abstract
Thirteen children, mean age 10.9 yr, with perennial asthma, were studied with respect to the duration of the bronchodilating effect of formoterol, a new long-acting .beta.2 agonist for inhalation. The duration of action of formoterol metered dose aerosol (12 .mu.g) was compared with salbutamol metered dose aerosol (200 .mu.g) in a double-blind cross-over study. Formoterol was found to have significantly better bronchodilating effect 8 hr (P < 0.01) and 12 hr (P < 0.05) after inhalation of the drug. Formoterol (24 .mu.g) was given single-blindly on the third trial day and showed a tendency towards a better bronchodilating effect (n.s.) than formoterol (12 .mu.g). There was no difference between the treatments with regard to adverse reactions such as tremor, palpitations, raised heart rate or anxiety. Formoterol proved to be superior to salbutamol as long-acting bronchodilator in children with bronchial asthma.